^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    γδ TCR modulator

    Related drugs:
    Apply
    A Study of SGN-EGFRd2 in Advanced Solid Tumors (SGNEGFRd2-001) (NCT05983133)
    Phase 1
    Seagen Inc.
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    11/14/2023
    Primary completion :
    07/31/2027
    Completion :
    09/30/2028
    EGFR • ALK • MSI
    |
    EGFR mutation • MSI-H/dMMR • ALK rearrangement
    |
    PF-08046052
    Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL (NCT05554939)
    Phase 1/2
    Chinese PLA General Hospital
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    12/11/2022
    Primary completion :
    12/31/2026
    Completion :
    12/31/2027
    BCL2 • CCND1 • BCL6
    |
    CD19 positive • Chr t(11;14)
    |
    cyclophosphamide • fludarabine IV • Mustargen (mechlorethamine)
    A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (CLN-619-001) (NCT05117476)
    Phase 1
    Cullinan Therapeutics Inc.
    Recruiting
    Last update posted :
    02/03/2025
    Initiation :
    10/29/2021
    Primary completion :
    03/01/2026
    Completion :
    06/01/2026
    EGFR • ALK
    |
    Keytruda (pembrolizumab) • CLN-619
    ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) (NCT06415487)
    Phase 1
    Acepodia Biotech, Inc.
    Not yet recruiting
    Last update posted :
    05/15/2024
    Initiation :
    05/31/2024
    Primary completion :
    12/18/2026
    Completion :
    03/25/2027
    IL2
    |
    Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • ACE2016
    T-Cell Therapy (ECT204) in Adults With Advanced HCC (ARYA3) (NCT04864054)
    Phase 2
    Eureka Therapeutics Inc.
    Recruiting
    Last update posted :
    05/06/2024
    Initiation :
    03/11/2022
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    GPC3
    |
    GPC3 expression • GPC3 positive
    |
    cyclophosphamide • Stivarga (regorafenib) • ECT204
    Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC (NCT06193486)
    Phase 1
    H. Lee Moffitt Cancer Center and Research Insti...
    Recruiting
    Last update posted :
    03/13/2024
    Initiation :
    02/26/2024
    Primary completion :
    01/13/2029
    Completion :
    12/13/2033
    PSCA
    |
    cyclophosphamide • fludarabine IV
    ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma (ARYA-2) (NCT04634357)
    Phase 1/2
    Eureka Therapeutics Inc.
    Recruiting
    Last update posted :
    03/07/2024
    Initiation :
    07/19/2022
    Primary completion :
    01/31/2026
    Completion :
    01/31/2028
    AFP
    |
    ET140203
    ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies (NCT05653271)
    Phase 1
    Acepodia Biotech, Inc.
    Recruiting
    Last update posted :
    02/28/2024
    Initiation :
    01/21/2023
    Primary completion :
    09/01/2025
    Completion :
    09/01/2027
    CD20 • IFNG • IL6 • TNFA • IL2 • IL10
    |
    CD20 positive
    |
    Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV • ACE1831
    Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Stage 4 Metastatic NSCLC (NCT06069570)
    Phase 1
    Kiromic BioPharma Inc.
    Recruiting
    Last update posted :
    12/15/2023
    Initiation :
    11/07/2023
    Primary completion :
    10/01/2024
    Completion :
    01/01/2027
    EGFR • KRAS • BRAF • ALK • ROS1
    QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (NCT06056752)
    Phase 1
    Anhui Provincial Hospital
    Recruiting
    Last update posted :
    10/24/2023
    Initiation :
    09/27/2023
    Primary completion :
    07/03/2025
    Completion :
    07/03/2026
    IL6 • TNFA • IL2 • IL10
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV
    UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies. (NCT06092047)
    Phase 1
    PersonGen BioTherapeutics (Suzhou) Co., Ltd.
    Not yet recruiting
    Last update posted :
    10/20/2023
    Initiation :
    10/01/2023
    Primary completion :
    07/01/2026
    Completion :
    04/01/2028
    IL6
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV
    Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection (NCT06018363)
    Phase 1/2
    Dushu Lake Hospital Affiliated to Soochow Unive...
    Recruiting
    Last update posted :
    08/30/2023
    Initiation :
    06/01/2023
    Primary completion :
    12/31/2025
    Completion :
    12/31/2026
    IL6 • CD276 • IL10
    |
    CD276 expression
    |
    QH104
    UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (NCT05731219)
    Phase 1
    PersonGen BioTherapeutics (Suzhou) Co., Ltd.
    Recruiting
    Last update posted :
    02/16/2023
    Initiation :
    09/26/2022
    Primary completion :
    09/26/2023
    Completion :
    09/26/2025
    CD276
    |
    CD276 expression
    |
    UTAA06
    Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (NCT05722171)
    Phase 1
    PersonGen BioTherapeutics (Suzhou) Co., Ltd.
    Recruiting
    Last update posted :
    02/10/2023
    Initiation :
    12/27/2022
    Primary completion :
    12/27/2023
    Completion :
    12/27/2024
    CD276
    |
    CD276 expression
    |
    UTAA06
    A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients (NCT04688853)
    Phase 1
    Gadeta B.V.
    Active, not recruiting
    Last update posted :
    09/08/2022
    Initiation :
    05/13/2021
    Primary completion :
    07/30/2023
    Completion :
    07/30/2024
    IL6
    |
    GDT002
    Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA) (NCT05302037)
    Phase 1
    CytoMed Therapeutics Pte Ltd
    Not yet recruiting
    Last update posted :
    03/31/2022
    Initiation :
    04/01/2022
    Primary completion :
    03/01/2023
    Completion :
    12/01/2023
    NKG2D
    |
    CTM-N2D
    ET1402L1-ARTEMIS™2 T Cells in Alpha Fetoprotein (AFP) Expressing Hepatocellular Carcinoma (NCT03888859)
    Phase 1
    First Affiliated Hospital Xi'an Jiaotong Univer...
    Completed
    Last update posted :
    03/29/2021
    Initiation :
    12/06/2017
    Primary completion :
    04/13/2019
    Completion :
    12/08/2020
    HLA-A • IFNG • IL6 • TNFA • AFP • IL2 • IL10 • IL4
    |
    HLA-A*02 • AFP expression
    |
    ET1402L1-ARTEMIS T cells
    CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors (NCT04702841)
    Phase 1
    PersonGen BioTherapeutics (Suzhou) Co., Ltd.
    Recruiting
    Last update posted :
    03/08/2021
    Initiation :
    06/03/2020
    Primary completion :
    06/01/2022
    Completion :
    12/01/2022
    CD7
    |
    CD7-UCAR-γδT cells • γδT Cell infusion • γδT Cell infusion agent
    ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver Cancer (NCT03965546)
    Phase 1
    First Affiliated Hospital Xi'an Jiaotong Univer...
    Unknown status
    Last update posted :
    08/08/2019
    Initiation :
    05/30/2019
    Primary completion :
    06/01/2021
    Completion :
    06/01/2022
    HLA-A • IFNG • IL6 • TNFA • AFP • IL2 • IL10
    |
    HLA-A*02 • AFP expression • IL10 elevation • IL2 expression • IL6 expression
    |
    sorafenib • ET1402L1-ARTEMIS T cells
    Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLL (NCT02656147)
    Phase 1
    Beijing Doing Biomedical Co., Ltd.
    Unknown status
    Last update posted :
    09/05/2017
    Initiation :
    10/01/2017
    Primary completion :
    04/01/2019
    Completion :
    04/01/2020
    CD19
    |
    CD19 expression
    |
    Gamma delta T-cells • anti-CD19-CAR γδT